How to mitigate risk during ADC development with multi-parameter stability characterization

October 24, 2023

There are unique concerns about the developability properties of antibody-drug conjugates (ADCs) due to the conjugation process.

With multi-parameter assessment of CQAs, it is possible to examine multiple aspects of ADC stability in parallel, to ensure the final product has the greatest chance at clinical success, while saving time and sample early in development.

In this webinar, Product Manager Rebecca Hood dives into the practical considerations of ADC development and characterization.

You’ll learn:

  • What formulation considerations are critical during ADC development
  • How to use high-resolution stability data to compare your ADCs to unconjugated antibodies
  • Which characteristics are impacted by the conjugation process, and how they influence your selection and development process

Check out further video resources from this webinar:

Previous Video
Conversation:  How Aaron Frimel from Thermo Fisher Scientific approaches biologics formulation
Conversation: How Aaron Frimel from Thermo Fisher Scientific approaches biologics formulation

Join this conversation to gain insight into how the Analytical and Formulation Sciences team at Thermo Fish...

Up next
nanoDSF for biologics: How to interpret thermal unfolding profiles for your different applications
nanoDSF for biologics: How to interpret thermal unfolding profiles for your different applications

Thermal stability screening is a common approach used to study the developability of a wide range of protei...